Patents by Inventor Philippe Despres
Philippe Despres has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11779640Abstract: The present invention relates to a lentiviral vector-based Japanese encephalitis (JE) immunogenic composition. The present invention is directed to a recombinant lentiviral vector expressing the precursor of membrane (prM) and the envelope (E) protein, in particular glycoprotein of a Japanese encephalitis virus (JEV) or immunogenic fragments thereof. The present invention also provides cells expressing the lentiviral vector, uses and methods to prevent a JEV infection in a mammalian host, especially in a human or an animal host, in particular a pig or a piglet, preferably a domestic pig or a domestic piglet.Type: GrantFiled: February 19, 2020Date of Patent: October 10, 2023Assignees: INSTITUT PASTEUR, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUEInventors: Pierre Charneau, Philippe Despres, Melissanne De Wispelaere, Philippe Souque, Marie-Pascale Frenkiel
-
Patent number: 10849943Abstract: The present invention relates to vaccine compositions comprising an attenuated mutant Zika virus. The inventors have introduced mutations at very specific positions that abrogate the N-glycosylation site on the E protein of the epidemic strain which will prevent the generation of auto-antibodies responsible for Guillain-Barre syndrome. The inventors have also produced additional mutations of the virus that result to a dramatic reduction of the cytopathic effects without affecting the capacity to produce high titers of virus. In particular, the present invention relates to an attenuated mutant Zika virus comprising a protein E of the epidemic strain wherein at least one amino acid residue at position 152, 156 or 158 is mutated.Type: GrantFiled: June 22, 2017Date of Patent: December 1, 2020Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE DE LA REUNION SAINT DENIS, INSTITUT DE RECHERCHE POUR LE DEVELOPPEMENT (IRD), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE-CNRSInventors: Philippe Despres, Gilles Gadea, Patrick Mavingui, Wildriss Viranaicken
-
Publication number: 20200230228Abstract: The present invention relates to a lentiviral vector-based Japanese encephalitis (JE) immunogenic composition. The present invention is directed to a recombinant lentiviral vector expressing the precursor of membrane (prM) and the envelope (E) protein, in particular glycoprotein of a Japanese encephalitis virus (JEV) or immunogenic fragments thereof. The present invention also provides cells expressing the lentiviral vector, uses and methods to prevent a JEV infection in a mammalian host, especially in a human or an animal host, in particular a pig or a piglet, preferably a domestic pig or a domestic piglet.Type: ApplicationFiled: February 19, 2020Publication date: July 23, 2020Inventors: Pierre CHARNEAU, Philippe DESPRES, Melissanne DE WISPELAERE, Philippe SOUQUE, Marie-Pascale FRENKIEL
-
Patent number: 10603374Abstract: The present invention relates to a lentiviral vector-based Japanese encephalitis (JE) immunogenic composition. The present invention is directed to a recombinant lentiviral vector expressing the precursor of membrane (prM) and the envelope (E) protein, in particular glycoprotein of a Japanese encephalitis virus (JEV) or immunogenic fragments thereof. The present invention also provides cells expressing the lentiviral vector, uses and methods to prevent a JEV infection in a mammalian host, especially in a human or an animal host, in particular a pig or a piglet, preferably a domestic pig or a domestic piglet.Type: GrantFiled: December 7, 2015Date of Patent: March 31, 2020Assignees: INSTITUT PASTEUR, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUEInventors: Pierre Charneau, Philippe Despres, Melissanne De Wispelaere, Philippe Souque, Marie-Pascale Frenkiel
-
Patent number: 10590174Abstract: The present invention relates to a genomic sequences encoding for an attenuated mutant Zika virus. The inventors have introduced some specific substitutions at very specific positions in the epidemic genomic sequence for restoring some fixation sites for miR-4279 that were originally present in the endemic genomic sequence. Moreover the inventors have additionally introduced mutation leading to the abrogation of the N-glycosylation site on the E protein which will prevent the generation of auto-antibodies responsible for Guillain-Barre syndrome. The inventors have produced additional mutations of the virus that result to a dramatic reduction of the cytopathic effects without affecting the capacity to produce high titers of virus. In particular the present invention relates to a genomic sequence characterized by the sequence represented by SEQ ID NO:1 wherein at least one site of fixation for miR-4279 is restored.Type: GrantFiled: July 7, 2017Date of Patent: March 17, 2020Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), UNIVERSITE DE LA REUNION SAINT DENIS, INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT (IRD), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)Inventors: Gilles Gadea, Michael Girardot, Philippe Despres
-
Publication number: 20190255125Abstract: The present invention relates to vaccine compositions comprising an attenuated mutant Zika virus. The inventors have introduced mutations at very specific positions that abrogate the N-glycosylation site on the E protein of the epidemic strain which will prevent the generation of auto-antibodies responsible for Guillain-Barre syndrome. The inventors have also produced additional mutations of the virus that result to a dramatic reduction of the cytopathic effects without affecting the capacity to produce high titers of virus. In particular, the present invention relates to an attenuated mutant Zika virus comprising a protein E of the epidemic strain wherein at least one amino acid residue at position 152, 156 or 158 is mutated.Type: ApplicationFiled: June 22, 2017Publication date: August 22, 2019Inventors: Philippe DESPRES, Gilles GADEA, Patrick MAVINGUI, Wildriss VIRANAICKEN
-
Patent number: 10352930Abstract: The present invention provides an immunoassay leading to the rapid and simultaneous detection of antibodies to a wide range of infectious pathogens in biological fluids of infected patients. This immunoassay involves the covalent and oriented coupling of fusion proteins comprising an AGT enzyme and a viral antigen on an identifiable solid support (e.g. fluorescent microspheres). The thus obtained antigen-coupled microspheres show enhanced capture of specific antibodies as compared to antigen-coupled microspheres produced by standard amine coupling procedures.Type: GrantFiled: July 19, 2017Date of Patent: July 16, 2019Assignee: INSTITUT PASTEURInventors: Jean-Claude Manuguerra, Jessica Vanhomwegen, Philippe Despres, Sylvie Paulous
-
Publication number: 20190177373Abstract: The present invention relates to a genomic sequences encoding for an attenuated mutant Zika virus. The inventors have introduced some specific substitutions at very specific positions in the epidemic genomic sequence for restoring some fixation sites for miR-4279 that were originally present in the endemic genomic sequence. Moreover the inventors have additionally introduced mutation leading to the abrogation of the N-glycosylation site on the E protein which will prevent the generation of auto-antibodies responsible for Guillain-Barre syndrome. The inventors have produced additional mutations of the virus that result to a dramatic reduction of the cytopathic effects without affecting the capacity to produce high titers of virus. In particular the present invention relates to a genomic sequence characterized by the sequence represented by SEQ ID NO:1 wherein at least one site of fixation for miR-4279 is restored.Type: ApplicationFiled: July 7, 2017Publication date: June 13, 2019Inventors: Gilles GADEA, Michael GIRARDOT, Philippe DESPRES
-
Patent number: 10227385Abstract: The invention relates to building a chimeric polypeptide used for preventing or treating a Flaviviridae infection. The use of the inventive chimeric polypeptide for producing recombinant viral vectors such as a measles living viral vector is also disclosed.Type: GrantFiled: January 18, 2017Date of Patent: March 12, 2019Assignees: INSTITUT PASTEUR, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUEInventors: Frederic Tangy, Marianne Lucas-Hourani, Erika Navarro-Sanchez, Marie-Pascale Frenkiel, Hugues Bedouelle, Chantal Combredet, Philippe Despres
-
Patent number: 10209248Abstract: The present invention provides an immunoassay leading to the rapid and simultaneous detection of antibodies to a wide range of infectious pathogens in biological fluids of infected patients. This immunoassay involves the covalent and oriented coupling of fusion proteins comprising an AGT enzyme and a viral antigen on an identifiable solid support (e.g. fluorescent microspheres). The thus obtained antigen-coupled microspheres show enhanced capture of specific antibodies as compared to antigen-coupled microspheres produced by standard amine coupling procedures.Type: GrantFiled: July 19, 2017Date of Patent: February 19, 2019Assignee: Institut PasteurInventors: Jean-Claude Manuguerra, Jessica Vanhomwegen, Philippe Despres, Sylvie Paulous
-
Patent number: 10197562Abstract: The present invention provides an immunoassay leading to the rapid and simultaneous detection of antibodies to a wide range of infectious pathogens in biological fluids of infected patients. This immunoassay involves the covalent and oriented coupling of fusion proteins comprising an AGT enzyme and a viral antigen on an identifiable solid support (e.g. fluorescent microspheres). The thus obtained antigen-coupled microspheres show enhanced capture of specific antibodies as compared to antigen-coupled microspheres produced by standard amine coupling procedures.Type: GrantFiled: April 6, 2017Date of Patent: February 5, 2019Assignee: INSTITUT PASTEURInventors: Jean-Claude Manuguerra, Jessica Vanhomwegen, Philippe Despres, Sylvie Paulous
-
Patent number: 10119967Abstract: The present invention provides kits and assay methods for the early detection of pathogens, precise identification of the etiologic agent, and improved disease surveillance. More specifically, the present invention discloses an immunoassay leading to the rapid and simultaneous detection of antibodies to a wide range of infectious pathogens in biological fluids of infected patients. This immunoassay involves the covalent and oriented coupling of fusion proteins comprising an AGT enzyme and a viral antigen on an identifiable solid support (e.g. fluorescent microspheres), said support being previously coated with an AGT substrate. This coupling is mediated by the irreversible reaction of the AGT enzyme on its substrate. The thus obtained antigen-coupled microspheres show enhanced capture of specific antibodies as compared to antigen-coupled microspheres produced by standard amine coupling procedures.Type: GrantFiled: May 3, 2013Date of Patent: November 6, 2018Assignee: Institut PasteurInventors: Jean-Claude Manuguerra, Jessica Vanhomwegen, Philippe Despres, Sylvie Paulous
-
Patent number: 10017769Abstract: The present invention relates to a novel enhancer of protein production in host cells. It discloses a vector for expressing recombinant proteins in these cells, comprising a nucleotide sequence encoding a) a secretion peptidic signal, b) a 6-methylguanine-DNA-methyltransferase enzyme (MGMT, EC 2.1.1.63), a mutant or a catalytic domain thereof, and c) a recombinant protein. Said MGMT enzyme is preferably the so-called SNAP protein.Type: GrantFiled: December 13, 2016Date of Patent: July 10, 2018Assignee: INSTITUT PASTEURInventors: Philippe Despres, Sylvie Paulous, Elodie Crublet
-
Publication number: 20180038852Abstract: The present invention provides kits and assay methods for the early detection of pathogens, precise identification of the etiologic agent, and improved disease surveillance. More specifically, the present invention discloses an immunoassay leading to the rapid and simultaneous detection of antibodies to a wide range of infectious pathogens in biological fluids of infected patients. This immunoassay involves the covalent and oriented coupling of fusion proteins comprising an AGT enzyme and a viral antigen on an identifiable solid support (e.g. fluorescent microspheres), said support being previously coated with an AGT substrate. This coupling is mediated by the irreversible reaction of the AGT enzyme on its substrate. The thus obtained antigen-coupled microspheres show enhanced capture of specific antibodies as compared to antigen-coupled microspheres produced by standard amine coupling procedures.Type: ApplicationFiled: July 19, 2017Publication date: February 8, 2018Applicant: INSTITUT PASTEURInventors: Jean-Claude Manuguerra, Jessica Vanhomwegen, Philippe Despres, Sylvie Paulous
-
Publication number: 20170336412Abstract: The present invention provides kits and assay methods for the early detection of pathogens, precise identification of the etiologic agent, and improved disease surveillance. More specifically, the present invention discloses an immunoassay leading to the rapid and simultaneous detection of antibodies to a wide range of infectious pathogens in biological fluids of infected patients. This immunoassay involves the covalent and oriented coupling of fusion proteins comprising an AGT enzyme and a viral antigen on an identifiable solid support (e.g. fluorescent microspheres), said support being previously coated with an AGT substrate. This coupling is mediated by the irreversible reaction of the AGT enzyme on its substrate. The thus obtained antigen-coupled microspheres show enhanced capture of specific antibodies as compared to antigen-coupled microspheres produced by standard amine coupling procedures.Type: ApplicationFiled: July 19, 2017Publication date: November 23, 2017Applicant: Institut PasteurInventors: Jean-Claude MANUGUERRA, Jessica VANHOMWEGEN, Philippe DESPRES, Sylvie PAULOUS
-
Publication number: 20170319681Abstract: The present invention relates to a lentiviral vector-based Japanese encephalitis (JE) immunogenic composition. The present invention is directed to a recombinant lentiviral vector expressing the precursor of membrane (prM) and the envelope (E) protein, in particular glycoprotein of a Japanese encephalitis virus (JEV) or immunogenic fragments thereof. The present invention also provides cells expressing the lentiviral vector, uses and methods to prevent a JEV infection in a mammalian host, especially in a human or an animal host, in particular a pig or a piglet, preferably a domestic pig or a domestic piglet.Type: ApplicationFiled: December 7, 2015Publication date: November 9, 2017Inventors: Pierre CHARNEAU, Philippe DESPRES, Melissanne DE WISPELAERE, Philippe SOUQUE, Marie-Pascale FRENKIEL
-
Publication number: 20170276672Abstract: The present invention provides kits and assay methods for the early detection of pathogens, precise identification of the etiologic agent, and improved disease surveillance. More specifically, the present invention discloses an immunoassay leading to the rapid and simultaneous detection of antibodies to a wide range of infectious pathogens in biological fluids of infected patients. This immunoassay involves the covalent and oriented coupling of fusion proteins comprising an AGT enzyme and a viral antigen on an identifiable solid support (e.g. fluorescent microspheres), said support being previously coated with an AGT substrate. This coupling is mediated by the irreversible reaction of the AGT enzyme on its substrate. The thus obtained antigen-coupled microspheres show enhanced capture of specific antibodies as compared to antigen-coupled microspheres produced by standard amine coupling procedures.Type: ApplicationFiled: April 6, 2017Publication date: September 28, 2017Applicant: INSTITUT PASTEURInventors: Jean-Claude Manuguerra, Jessica Vanhomwegen, Philippe Despres, Sylvie Paulous
-
Patent number: 9655961Abstract: The invention relates to recombinant Measles virus expressing Chikungunya virus polypeptides, and concerns in particular virus like particles (VLP) that contain envelope and capsid proteins of a Chikungunya virus at their surface. These particles are recombinant infectious particles able to replicate in a host after an administration. The invention provides means, in particular nucleic acids, vectors, cells and rescue systems to produce these recombinant infectious particles. The invention also relates to the use of these recombinant infectious particles, in particular under the form of a composition, more particularly in a vaccine formulation, for the treatment or prevention of an infection by Chikungunya virus.Type: GrantFiled: September 26, 2013Date of Patent: May 23, 2017Assignees: INSTITUT PASTEUR, THEMIS BIOSCIENCE GMBH, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUEInventors: Frederic Tangy, Samantha Brandler, Philippe Despres, Andre Habel
-
Publication number: 20170121375Abstract: The invention relates to building a chimeric polypeptide used for preventing or treating a Flaviviridae infection. The use of the inventive chimeric polypeptide for producing recombinant viral vectors such as a measles living viral vector is also disclosed.Type: ApplicationFiled: January 18, 2017Publication date: May 4, 2017Inventors: Frederic TANGY, Marianne LUCAS-HOURANI, Erika NAVARRO-SANCHEZ, Marie-Pascale FRENKIEL, Hugues BEDOUELLE, Chantal COMBREDET, Philippe DESPRES
-
Patent number: 9638692Abstract: The present invention provides kits and assay methods for the early detection of pathogens, precise identification of the etiologic agent, and improved disease surveillance. More specifically, the present invention discloses an immunoassay leading to the rapid and simultaneous detection of antibodies to a wide range of infectious pathogens in biological fluids of infected patients. This immunoassay involves the covalent and oriented coupling of fusion proteins comprising an AGT enzyme and a viral antigen on an identifiable solid support (e.g. fluorescent microspheres), said support being previously coated with an AGT substrate. This coupling is mediated by the irreversible reaction of the AGT enzyme on its substrate. The thus obtained antigen-coupled microspheres show enhanced capture of specific antibodies as compared to antigen-coupled microspheres produced by standard amine coupling procedures.Type: GrantFiled: December 10, 2012Date of Patent: May 2, 2017Assignee: INSTITUT PASTEURInventors: Jean-Claude Manuguerra, Jessica Vanhomwegen, Philippe Despres, Sylvie Paulous